Exenatide phase iii trial

[Obiora]

Hi everyone, im nervously awaiting the exenatide phase iii trial results and as I understand it, the trial ended on the 31/07 of this year but no information has come about it, any idea if this is usual?

[SallyBeeBobs]

I didn't realise the results of the phase 3 were out this year. Fingers crossed it's good news!

I just read this...

rorycellanjones.substack.co...

Do you think it will be available soon if the trial was successful?

[DEAT]

Very interesting read. Thanks for posting 💓

I'm one of those PWP that will lose their rag if I get told that again.

[7springshollow]

I'm in stem cell trials and it can take up to a year for results

[seamusw in reply to 7springshollow]

Which trial?

[7springshollow in reply to seamusw]

It's through Hope Bioscience in sugar land Texas

[Ghmac in reply to 7springshollow]

How is it going for you?

[7springshollow in reply to Ghmac]

Very well. I've only had the 1 spinal infusion and am cutting my meds often, sleeping better and having longer on times

[Lyricist]

my UK Neurologist who is one of the most highly regarded experts in the Parkinson arena says he has had discussions with the Exenatide team and described himself as (1) “excited” by the results so far, (2) expecting significant results from phase 3, (3) keen to prescribe Exenatide asap and (4) expecting to able to do so before the end of 2024. We shall see!

[Obiora in reply to Lyricist]

So happy to hear this!

[SallyBeeBobs in reply to Lyricist]

That really does sound promising!

[Buckholt]

Surprised that there has been no leaking of results. Excited researchers usually let something slip.

[SallyBeeBobs]

Is there anybody on here who has used diabetes meds for diabetes but has PD as well? I wonder if they have offered any anecdotal insight as to whether their PD symptoms have been slowed as a result of the meds. It can't be that unusual to be medicated for both diabetes and PD?

[Patient100]

Usually clinical trial results take a while to be released because although the clinical trial may have ended, data need to be cleaned before the clinical trial database can be locked and then some extra time needs to be spent on the data analyses, more so in the case of pivotal Phase 3 trials that are seeking regulatory authority (FDA) approval.

[Practiced]

It does take a few months for a study to go from completion to publication. I believe that these drugs (GLP 1 agonists) do something positive.

I went on exenatide soon after the phase 2 trial came out (it was a really nice little trial) and stayed on it till I could no longer obtain it in Australia. I then took semaglutide but that may not have been a good choice due to its limited ability to cross the blood brain barrier. So I have been on one or the other for nearly 7 years. I have had PD for 11 years and am on a light to medium amount of Rx. My symptoms are pretty much fully controlled apart from a messed up sleep wake cycle. I continue to work and people don't realise I have PD. My neurologist hasn't been excited by exenatide and thinks I'm just lucky to be progressing slower than average. I prefer to think the injections have helped. I write this for 2 reasons 1. To say that long term exenatide/semaglutide has not completely stopped progression of my PD but progression is very slow. Secondly I'm curious to know if there are other long term users out there and what is your experience?

[Kwisatz]

I injected myself with exenatide once a week for two years. It had no effect.

[SallyBeeBobs in reply to Kwisatz]

Did your PD symptoms worsen on it Kwisatz, or just not improve?

[Cardiology]

cureparkinsons.org.uk/exena...

Exenatide phase 3 trial results shared with participants

Trial participants learned from the lead investigator that the Exenatide-PD3 study did not meet its primary end point (this is the predetermined measure of success). The results indicate that there was no significant difference in the progression of motor symptoms between the treatment and placebo groups (those not taking active drug). There was also no difference between the groups with any of the other measures included in this trial.

These results have been submitted to a scientific journal for publication.

The study team is now working to understand the disconnect between the encouraging phase 2 results with exenatide, the clinical success in Parkinson’s patients of another GLP-1R agonist lixisenatide, and these new phase 3 results with exenatide. They also are working to identify all learnings from this trial to inform future research in the GLP-1 field and beyond.

Results of two sub-studies, funded by Cure Parkinson’s with Van Andel Institute (VAI), are still forthcoming.

[Obiora in reply to Cardiology]

Thanks for the update, cardiology!